0IL6.L $135.00 0.6711%
MLR $34.50 -0.5048%
LEX.L $8.50 3.0303%
1561.HK $1.31 5.6452%
CTV $0.89 -0.7486%
0K05.L $88.78 1.3701%
8039.HK $0.47 -15.4545%
FXZ $60.06 -0.2822%
SYPR $1.95 1.5625%
DECB.BR $2.25 -0.6623%
CRUD.L $8.21 -1.499%
CNGLU $10.47 0%
DWFI $25.82 0%
EQX $5.29 0.8588%
WEIX $21.14 1.2867%
CMC $43.70 0.2984%
PSA $292.88 -0.7186%
1293.HK $0.35 1.4493%
EVCM $11.67 -4.5789%
SPCB $1.09 1.8692%
ACV $18.87 -0.3696%
2307.HK $0.30 3.4483%
ENJ $23.67 -1.375%
SMP $35.75 -0.5287%
GO $30.16 0.7012%
WEGE3.SA $38.90 -1.0682%
LEV $2.05 -5.0926%
SHYG.L $78.34 -0.2165%
8126.HK $0.15 0%
AMPL $10.04 -2.2882%
FASA.L $4 904.25 0%
DOO $43.44 0%
IIAC-UN $10.73 0%
HCO.PA $4.98 -0.7968%
SINO $4.19 0%
1527.HK $0.91 -9%
BANR $41.79 -0.9716%
1123.HK $0.13 0%
AKBA $1.12 5.6604%
LFT $1.74 4.1916%
TEL $119.70 -0.2999%
ENLV $2.78 -1.5957%
L6EW.L $9 602.00 -0.27%
BIOTW $0.01 0%
BSY $44.63 -1.3047%
PRIC.L $1 543.84 -0.2175%
BML-PG $20.23 0.8801%
RORO $16.49 -0.4047%
XCEM $26.94 -0.3053%
6078.HK $52.00 -1.7013%
OST $1.12 -4.0427%
NTEC $9.63 0%
8146.HK $0.16 -3.0303%
NAD $11.24 -0.2016%
0P0000KM24.L $14 447.80 0.4107%
BOBR4.SA $1.53 6.993%
UBOH $18.30 -2.6596%
0931.HK $0.33 -1.4925%
RS2U.PA $254.58 0.1377%
SPHQ $47.07 -0.5493%
0RT7.L $19.97 0%
GPM.L $34.50 0%
SXUS $18.00 0%
XFOR $1.47 -1.6779%
NSL $4.51 0.2758%
8136.HK $0.04 0%
6839.HK $0.30 -1.6667%
BHIL $1.44 -11.9632%
GIB $102.37 -0.1901%
WOW $7.96 1.7903%
HYLA.L $5.30 -0.3949%
0IYU.L $0.20 -9.7273%
ENCG.L $1 043.50 -0.4864%
BLHY $20.85 -0.2154%
1096.HK $0.03 0%
VIC.L $77.00 -0.3881%
CWEB $36.78 -5.7648%
AVG.L $410.00 0%
IVES $31.05 -1.2405%
CDAQ $10.26 0%
SIFI $43.06 0%
CGL.L $73.00 -2.6667%
TRMR $5.30 -4.3321%
WMC.CN $0.06 0%
LUXU.PA $227.84 -1.0778%
PNTG $11.28 1.5302%
SILC $34.35 0.3213%
ENOB $1.18 1.7155%
FOU.BR $1.06 -14.5161%
GET $1.88 0%
9979.HK $7.10 -0.9763%
VTC $76.04 -0.4191%
6162.HK $0.13 -11.3333%
WEL $10.64 0.047%
HIPS $11.27 -1.097%
0665.HK $0.69 -1.4286%
MMM.L $3.90 0%
FOG.L $9.70 -0.5128%
0OA7.L $44.85 1.24%
Eng
Логотип
Eng
Лого

Neovacs S.A. ALNEV.PA

$0.00

На 18:01, 12 мая 2023

Ранг: 3

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    496982.00000000

  • week52high

    0.39

  • week52low

    0.00

  • Revenue

    22595

  • P/E TTM

    0

  • Beta

    -0.00381600

  • EPS

    2.77000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    02 окт 2019 г. в 21:00

Описание компании

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек